ZOMIG is indicated for the acute treatment of migraine with or without
aura in adults.
ZOMIG should only be used where a clear diagnosis of migraine has been
ZOMIG should not be administered to patients with hemiplegic or basilar
ZOMIG, like other compounds in this class, should not be given
to patients in whom unrecognized coronary artery disease (CAD) is
predicted by risk factors unless a cardiovascular evaluation provides
satisfactory clinical evidence that the patient is reasonably free of
coronary artery and ischemic myocardial disease or other significant
underlying cardiovascular disease.
Phenylketonurics: ZOMIG-ZMT Tablets contain phenylalanine.
The most common side effects associated with taking ZOMIG and ZOMIG-ZMT
include dizziness; tightness, pressure, pain in the neck, throat, or jaw;
fatigue; tingling; drowsiness; or nausea.